Categories

Modified mRNA Encapsulated mRNA mRNA Enzyme SARS-CoV-2 Pseudovirus Popular Products Antibodies DNA Binding Proteins Electrophoresis Genome Engineering Polymerases Recombinases Transcription Factors Transfection

Services

Custom Cloning Virus Production Protein Purification Protein Expression

Product 31/43

Previous Return to the Product List Next

Return to the Product List

Pfizer-BioNTech BNT162b2 SARS-CoV-2 Spike Glycoprotein mRNA

Cat #: EG-331

Size

Qty

Product Name	SARS-CoV-2 Spike Glycoprotein mRNA (Similar to BNT162b2 mRNA manufactured by Pfizer-BioNTech)
Description	This modified mRNA encodes the full-length SARS-CoV-2 spike glycoprotein with K986P and V987P mutations to ensure the resulting S glycoprotein in an antigenically optimal pre-fusion conformation
Features	5' Cap: Capped with ARCA (Anti Reverse Cap Analog, m7(3'-O-methyl)-G(5')ppp(5')G, Cap 0) or CleanCap AG (m7G(5')ppp(5')(2'OMeA)pG, Cap 1) Optional modififications: Cy5 or Cy3 5â€™-UTR: derived from human alpha-globin RNA with an optimized Kozak sequence Codon Optimization: Human Mutations: K986P and V987P to ensure the S glycoprotein remains in an antigenically optimal pre-fusion conformation Nucleotide Modifications: mRNA modified with both Pseudo-UTP and 5mCTP 3â€™-UTR: comprises two sequence elements derived from the amino-terminal enhancer of split (AES) mRNA and the mitochondrial encoded 12S ribosomal RNA to confer RNA stability and high total protein expression. PolyA: 180 nt
Sequence	GAGAAÎ¨AAAC Î¨AGÎ¨AÎ¨Î¨CÎ¨Î¨ CÎ¨GGÎ¨CCCCA CAGACÎ¨CAGA GAGAACCCGC 50 CACCAÎ¨GÎ¨Î¨C GÎ¨GÎ¨Î¨CCÎ¨GG Î¨GCÎ¨GCÎ¨GCC Î¨CÎ¨GGÎ¨GÎ¨CC AGCCAGÎ¨GÎ¨G 100 Î¨GAACCÎ¨GAC CACCAGAACA CAGCÎ¨GCCÎ¨C CAGCCÎ¨ACAC CAACAGCÎ¨Î¨Î¨ 150 ACCAGAGGCG Î¨GÎ¨ACÎ¨ACCC CGACAAGGÎ¨G Î¨Î¨CAGAÎ¨CCA GCGÎ¨GCÎ¨GCA 200 CÎ¨CÎ¨ACCCAG GACCÎ¨GÎ¨Î¨CC Î¨GCCÎ¨Î¨Î¨CÎ¨Î¨ CAGCAACGÎ¨G ACCÎ¨GGÎ¨Î¨CC 250 ACGCCAÎ¨CCA CGÎ¨GÎ¨CCGGC ACCAAÎ¨GGCA CCAAGAGAÎ¨Î¨ CGACAACCCC 300 GÎ¨GCÎ¨GCCCÎ¨ Î¨CAACGACGG GGÎ¨GÎ¨ACÎ¨Î¨Î¨ GCCAGCACCG AGAAGÎ¨CCAA 350 CAÎ¨CAÎ¨CAGA GGCÎ¨GGAÎ¨CÎ¨ Î¨CGGCACCAC ACÎ¨GGACAGC AAGACCCAGA 400 GCCÎ¨GCÎ¨GAÎ¨ CGÎ¨GAACAAC GCCACCAACG Î¨GGÎ¨CAÎ¨CAA AGÎ¨GÎ¨GCGAG 450 Î¨Î¨CCAGÎ¨Î¨CÎ¨ GCAACGACCC CÎ¨Î¨CCÎ¨GGGC GÎ¨CÎ¨ACÎ¨ACC ACAAGAACAA 500 CAAGAGCÎ¨GG AÎ¨GGAAAGCG AGÎ¨Î¨CCGGGÎ¨ GÎ¨ACAGCAGC GCCAACAACÎ¨ 550 GCACCÎ¨Î¨CGA GÎ¨ACGÎ¨GÎ¨CC CAGCCÎ¨Î¨Î¨CC Î¨GAÎ¨GGACCÎ¨ GGAAGGCAAG 600 CAGGGCAACÎ¨ Î¨CAAGAACCÎ¨ GCGCGAGÎ¨Î¨C GÎ¨GÎ¨Î¨Î¨AAGA ACAÎ¨CGACGG 650 CÎ¨ACÎ¨Î¨CAAG AÎ¨CÎ¨ACAGCA AGCACACCCC Î¨AÎ¨CAACCÎ¨C GÎ¨GCGGGAÎ¨C 700 Î¨GCCÎ¨CAGGG CÎ¨Î¨CÎ¨CÎ¨GCÎ¨ CÎ¨GGAACCCC Î¨GGÎ¨GGAÎ¨CÎ¨ GCCCAÎ¨CGGC 750 AÎ¨CAACAÎ¨CA CCCGGÎ¨Î¨Î¨CA GACACÎ¨GCÎ¨G GCCCÎ¨GCACA GAAGCÎ¨ACCÎ¨ 800 GACACCÎ¨GGC GAÎ¨AGCAGCA GCGGAÎ¨GGAC AGCÎ¨GGÎ¨GCC GCCGCÎ¨Î¨ACÎ¨ 850 AÎ¨GÎ¨GGGCÎ¨A CCÎ¨GCAGCCÎ¨ AGAACCÎ¨Î¨CC Î¨GCÎ¨GAAGÎ¨A CAACGAGAAC 900 GGCACCAÎ¨CA CCGACGCCGÎ¨ GGAÎ¨Î¨GÎ¨GCÎ¨ CÎ¨GGAÎ¨CCÎ¨C Î¨GAGCGAGAC 950 AAAGÎ¨GCACC CÎ¨GAAGÎ¨CCÎ¨ Î¨CACCGÎ¨GGA AAAGGGCAÎ¨C Î¨ACCAGACCA 1000 GCAACÎ¨Î¨CCG GGÎ¨GCAGCCC ACCGAAÎ¨CCA Î¨CGÎ¨GCGGÎ¨Î¨ CCCCAAÎ¨AÎ¨C 1050 ACCAAÎ¨CÎ¨GÎ¨ GCCCCÎ¨Î¨CGG CGAGGÎ¨GÎ¨Î¨C AAÎ¨GCCACCA GAÎ¨Î¨CGCCÎ¨C 1100 Î¨GÎ¨GÎ¨ACGCC Î¨GGAACCGGA AGCGGAÎ¨CAG CAAÎ¨Î¨GCGÎ¨G GCCGACÎ¨ACÎ¨ 1150 CCGÎ¨GCÎ¨GÎ¨A CAACÎ¨CCGCC AGCÎ¨Î¨CAGCA CCÎ¨Î¨CAAGÎ¨G CÎ¨ACGGCGÎ¨G 1200 Î¨CCCCÎ¨ACCA AGCÎ¨GAACGA CCÎ¨GÎ¨GCÎ¨Î¨C ACAAACGÎ¨GÎ¨ ACGCCGACAG 1250 CÎ¨Î¨CGÎ¨GAÎ¨C CGGGGAGAÎ¨G AAGÎ¨GCGGCA GAÎ¨Î¨GCCCCÎ¨ GGACAGACAG 1300 GCAAGAÎ¨CGC CGACÎ¨ACAAC Î¨ACAAGCÎ¨GC CCGACGACÎ¨Î¨ CACCGGCÎ¨GÎ¨ 1350 GÎ¨GAÎ¨Î¨GCCÎ¨ GGAACAGCAA CAACCÎ¨GGAC Î¨CCAAAGÎ¨CG GCGGCAACÎ¨A 1400 CAAÎ¨Î¨ACCÎ¨G Î¨ACCGGCÎ¨GÎ¨ Î¨CCGGAAGÎ¨C CAAÎ¨CÎ¨GAAG CCCÎ¨Î¨CGAGC 1450 GGGACAÎ¨CÎ¨C CACCGAGAÎ¨C Î¨AÎ¨CAGGCCG GCAGCACCCC Î¨Î¨GÎ¨AACGGC 1500 GÎ¨GGAAGGCÎ¨ Î¨CAACÎ¨GCÎ¨A CÎ¨Î¨CCCACÎ¨G CAGÎ¨CCÎ¨ACG GCÎ¨Î¨Î¨CAGCC 1550 CACAAAÎ¨GGC GÎ¨GGGCÎ¨AÎ¨C AGCCCÎ¨ACAG AGÎ¨GGÎ¨GGÎ¨G CÎ¨GAGCÎ¨Î¨CG 1600 AACÎ¨GCÎ¨GCA Î¨GCCCCÎ¨GCC ACAGÎ¨GÎ¨GCG GCCCÎ¨AAGAA AAGCACCAAÎ¨ 1650 CÎ¨CGÎ¨GAAGA ACAAAÎ¨GCGÎ¨ GAACÎ¨Î¨CAAC Î¨Î¨CAACGGCC Î¨GACCGGCAC 1700 CGGCGÎ¨GCÎ¨G ACAGAGAGCA ACAAGAAGÎ¨Î¨ CCÎ¨GCCAÎ¨Î¨C CAGCAGÎ¨Î¨Î¨G 1750 GCCGGGAÎ¨AÎ¨ CGCCGAÎ¨ACC ACAGACGCCG Î¨Î¨AGAGAÎ¨CC CCAGACACÎ¨G 1800 GAAAÎ¨CCÎ¨GG ACAÎ¨CACCCC Î¨Î¨GCAGCÎ¨Î¨C GGCGGAGÎ¨GÎ¨ CÎ¨GÎ¨GAÎ¨CAC 1850 CCCÎ¨GGCACC AACACCAGCA AÎ¨CAGGÎ¨GGC AGÎ¨GCÎ¨GÎ¨AC CAGGACGÎ¨GA 1900 ACÎ¨GÎ¨ACCGA AGÎ¨GCCCGÎ¨G GCCAÎ¨Î¨CACG CCGAÎ¨CAGCÎ¨ GACACCÎ¨ACA 1950 Î¨GGCGGGÎ¨GÎ¨ ACÎ¨CCACCGG CAGCAAÎ¨GÎ¨G Î¨Î¨Î¨CAGACCA GAGCCGGCÎ¨G 2000 Î¨CÎ¨GAÎ¨CGGA GCCGAGCACG Î¨GAACAAÎ¨AG CÎ¨ACGAGÎ¨GC GACAÎ¨CCCCA 2050 Î¨CGGCGCÎ¨GG AAÎ¨CÎ¨GCGCC AGCÎ¨ACCAGA CACAGACAAA CAGCCCÎ¨CGG 2100 AGAGCCAGAA GCGÎ¨GGCCAG CCAGAGCAÎ¨C AÎ¨Î¨GCCÎ¨ACA CAAÎ¨GÎ¨CÎ¨CÎ¨ 2150 GGGCGCCGAG AACAGCGÎ¨GG CCÎ¨ACÎ¨CCAA CAACÎ¨CÎ¨AÎ¨C GCÎ¨AÎ¨CCCCA 2200 CCAACÎ¨Î¨CAC CAÎ¨CAGCGÎ¨G ACCACAGAGA Î¨CCÎ¨GCCÎ¨GÎ¨ GÎ¨CCAÎ¨GACC 2250 AAGACCAGCG Î¨GGACÎ¨GCAC CAÎ¨GÎ¨ACAÎ¨C Î¨GCGGCGAÎ¨Î¨ CCACCGAGÎ¨G 2300 CÎ¨CCAACCÎ¨G CÎ¨GCÎ¨GCAGÎ¨ ACGGCAGCÎ¨Î¨ CÎ¨GCACCCAG CÎ¨GAAÎ¨AGAG 2350 CCCÎ¨GACAGG GAÎ¨CGCCGÎ¨G GAACAGGACA AGAACACCCA AGAGGÎ¨GÎ¨Î¨C 2400 GCCCAAGÎ¨GA AGCAGAÎ¨CÎ¨A CAAGACCCCÎ¨ CCÎ¨AÎ¨CAAGG ACÎ¨Î¨CGGCGG 2450 CÎ¨Î¨CAAÎ¨Î¨Î¨C AGCCAGAÎ¨Î¨C Î¨GCCCGAÎ¨CC Î¨AGCAAGCCC AGCAAGCGGA 2500 GCÎ¨Î¨CAÎ¨CGA GGACCÎ¨GCÎ¨G Î¨Î¨CAACAAAG Î¨GACACÎ¨GGC CGACGCCGGC 2550 Î¨Î¨CAÎ¨CAAGC AGÎ¨AÎ¨GGCGA Î¨Î¨GÎ¨CÎ¨GGGC GACAÎ¨Î¨GCCG CCAGGGAÎ¨CÎ¨ 2600 GAÎ¨Î¨Î¨GCGCC CAGAAGÎ¨Î¨Î¨A ACGGACÎ¨GAC AGÎ¨GCÎ¨GCCÎ¨ CCÎ¨CÎ¨GCÎ¨GA 2650 CCGAÎ¨GAGAÎ¨ GAÎ¨CGCCCAG Î¨ACACAÎ¨CÎ¨G CCCÎ¨GCÎ¨GGC CGGCACAAÎ¨C 2700 ACAAGCGGCÎ¨ GGACAÎ¨Î¨Î¨GG AGCAGGCGCC GCÎ¨CÎ¨GCAGA Î¨CCCCÎ¨Î¨Î¨GC 2750 Î¨AÎ¨GCAGAÎ¨G GCCÎ¨ACCGGÎ¨ Î¨CAACGGCAÎ¨ CGGAGÎ¨GACC CAGAAÎ¨GÎ¨GC 2800 Î¨GÎ¨ACGAGAA CCAGAAGCÎ¨G AÎ¨CGCCAACC AGÎ¨Î¨CAACAG CGCCAÎ¨CGGC 2850 AAGAÎ¨CCAGG ACAGCCÎ¨GAG CAGCACAGCA AGCGCCCÎ¨GG GAAAGCÎ¨GCA 2900 GGACGÎ¨GGÎ¨C AACCAGAAÎ¨G CCCAGGCACÎ¨ GAACACCCÎ¨G GÎ¨CAAGCAGC 2950 Î¨GÎ¨CCÎ¨CCAA CÎ¨Î¨CGGCGCC AÎ¨CAGCÎ¨CÎ¨G Î¨GCÎ¨GAACGA Î¨AÎ¨CCÎ¨GAGC 3000 AGACÎ¨GGACC CÎ¨CCÎ¨GAGGC CGAGGÎ¨GCAG AÎ¨CGACAGAC Î¨GAÎ¨CACAGG 3050 CAGACÎ¨GCAG AGCCÎ¨CCAGA CAÎ¨ACGÎ¨GAC CCAGCAGCÎ¨G AÎ¨CAGAGCCG 3100 CCGAGAÎ¨Î¨AG AGCCÎ¨CÎ¨GCC AAÎ¨CÎ¨GGCCG CCACCAAGAÎ¨ GÎ¨CÎ¨GAGÎ¨GÎ¨ 3150 GÎ¨GCÎ¨GGGCC AGAGCAAGAG AGÎ¨GGACÎ¨Î¨Î¨ Î¨GCGGCAAGG GCÎ¨ACCACCÎ¨ 3200 GAÎ¨GAGCÎ¨Î¨C CCÎ¨CAGÎ¨CÎ¨G CCCCÎ¨CACGG CGÎ¨GGÎ¨GÎ¨Î¨Î¨ CÎ¨GCACGÎ¨GA 3250 CAÎ¨AÎ¨GÎ¨GCC CGCÎ¨CAAGAG AAGAAÎ¨Î¨Î¨CA CCACCGCÎ¨CC AGCCAÎ¨CÎ¨GC 3300 CACGACGGCA AAGCCCACÎ¨Î¨ Î¨CCÎ¨AGAGAA GGCGÎ¨GÎ¨Î¨CG Î¨GÎ¨CCAACGG 3350 CACCCAÎ¨Î¨GG Î¨Î¨CGÎ¨GACAC AGCGGAACÎ¨Î¨ CÎ¨ACGAGCCC CAGAÎ¨CAÎ¨CA 3400 CCACCGACAA CACCÎ¨Î¨CGÎ¨G Î¨CÎ¨GGCAACÎ¨ GCGACGÎ¨CGÎ¨ GAÎ¨CGGCAÎ¨Î¨ 3450 GÎ¨GAACAAÎ¨A CCGÎ¨GÎ¨ACGA CCCÎ¨CÎ¨GCAG CCCGAGCÎ¨GG ACAGCÎ¨Î¨CAA 3500 AGAGGAACÎ¨G GACAAGÎ¨ACÎ¨ Î¨Î¨AAGAACCA CACAAGCCCC GACGÎ¨GGACC 3550 Î¨GGGCGAÎ¨AÎ¨ CAGCGGAAÎ¨C AAÎ¨GCCAGCG Î¨CGÎ¨GAACAÎ¨ CCAGAAAGAG 3600 AÎ¨CGACCGGC Î¨GAACGAGGÎ¨ GGCCAAGAAÎ¨ CÎ¨GAACGAGA GCCÎ¨GAÎ¨CGA 3650 CCÎ¨GCAAGAA CÎ¨GGGGAAGÎ¨ ACGAGCAGÎ¨A CAÎ¨CAAGÎ¨GG CCCÎ¨GGÎ¨ACA 3700 Î¨CÎ¨GGCÎ¨GGG CÎ¨Î¨Î¨AÎ¨CGCC GGACÎ¨GAÎ¨Î¨G CCAÎ¨CGÎ¨GAÎ¨ GGÎ¨CACAAÎ¨C 3750 AÎ¨GCÎ¨GÎ¨GÎ¨Î¨ GCAÎ¨GACCAG CÎ¨GCÎ¨GÎ¨AGC Î¨GCCÎ¨GAAGG GCÎ¨GÎ¨Î¨GÎ¨AG 3800 CÎ¨GÎ¨GGCAGC Î¨GCÎ¨GCAAGÎ¨ Î¨CGACGAGGA CGAÎ¨Î¨CÎ¨GAG CCCGÎ¨GCÎ¨GA 3850 AGGGCGÎ¨GAA ACÎ¨GCACÎ¨AC ACAÎ¨GAÎ¨GAC Î¨CGAGCÎ¨GGÎ¨ ACÎ¨GCAÎ¨GCA 3900 CGCAAÎ¨GCÎ¨A GCÎ¨GCCCCÎ¨Î¨ Î¨CCCGÎ¨CCÎ¨G GGÎ¨ACCCCGA GÎ¨CÎ¨CCCCCG 3950 ACCÎ¨CGGGÎ¨C CCAGGÎ¨AÎ¨GC Î¨CCCACCÎ¨CC ACCÎ¨GCCCCA CÎ¨CACCACCÎ¨ 4000 CÎ¨GCÎ¨AGÎ¨Î¨C CAGACACCÎ¨C CCAAGCACGC AGCAAÎ¨GCAG CÎ¨CAAAACGC 4050 Î¨Î¨AGCCÎ¨AGC CACACCCCCA CGGGAAACAG CAGÎ¨GAÎ¨Î¨AA CCÎ¨Î¨Î¨AGCAA 4100 Î¨AAACGAAAG Î¨Î¨Î¨AACÎ¨AAG CÎ¨AÎ¨ACÎ¨AAC CCCAGGGÎ¨Î¨G GÎ¨CAAÎ¨Î¨Î¨CG 4150 Î¨GCCAGCCAC ACCCÎ¨GGAGC Î¨AGCGGCCGC AAGCÎ¨GCÎ¨Î¨A CAÎ¨AGAACÎ¨C 4250 GCGGCGAÎ¨Î¨G GCAÎ¨GCCGCC Î¨Î¨AAAAÎ¨Î¨Î¨Î¨ Î¨AÎ¨Î¨Î¨Î¨AÎ¨Î¨Î¨ Î¨Î¨Î¨CÎ¨Î¨Î¨Î¨CÎ¨ 4300 Î¨Î¨CCGAAÎ¨CG GAÎ¨Î¨Î¨Î¨GÎ¨Î¨Î¨ Î¨Î¨AAÎ¨AÎ¨Î¨Î¨C AAAAAAAAAA AAAAAAAAAA 4350 AAAAACGCGA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA 4400 AAAAAAAAAÎ¨ Î¨AAÎ¨AAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA 4450 AAAAAAAAAA AAAAÎ¨Î¨AAÎ¨A AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA 4500 AAAAAAAAAA AAAAAAAAA 4519 Î¨ = Pseudo-UTP
Application	Animal Vaccine Research (Not for human use)
Concentration	~1 μg/μl
Transfection Protocol	Lipofectamine™ MessengerMAX™ Transfection Reagent Protocol
QC	Agarose gel electrophoresis
Shipping	Dry ice
Storage	-80 oC